甲地孕酮辅助恶性肿瘤放化疗的临床观察

Megestrol acetate adjuvant chemoradiotherapy in the treatment of malignant tumor

目的：探讨甲地孕酮联合放化疗对恶性肿瘤患者疗效及不良反应的影响。方法将71例恶性肿瘤患者随机分为治疗组36例和对照组35例。对照组采用单纯放、化疗治疗；治疗组放、化疗同时加用甲地孕酮治疗，疗程为3~8周，观察两组患者食欲、体质量、Karnofsky 评分、胃肠道反应改善、疼痛减轻、白细胞计数等指标变化。结果两组食欲改善、体质量变化、Karnofsky 评分、疼痛减轻、白细胞计数正常者比较，治疗组疗效明显优于对照组（ P ﹤0.05）。结论甲地孕酮对恶性肿瘤放化疗患者在保护骨髓、减轻消化道反应和提高生活质量等方面有显著的改善作用且无明显不良反应。

Objective To investigate the effects and adverse reaction of megestrol acetate adjuvant chemoradiotherapy in the treatment of malignant tumor. Methods Seventy-one malignant tumor patients were randomly divided into the control group（35 cases）and treatment group（36 cases）. Patients in treatment group were treated by simple chemoradiotherapy,and patients in control group were given megestrol acetate on the basis of chemoradiotherapy for 3 -8 weeks. The patient appetite,weight change,Karnofsky score,improve the gastrointestinal reaction,pain relief and normal WBC count was compared between the two groups. Results The effection of the patients’appetite,weight change,Karnofsky score,pain relief,WBC count in group of treatment was significantly better than that of control group（P﹤0. 05）. Conclusion Megestrol acetate adjuvant chemoradiother-apy in the treatment of malignant tumor has a significant role in improving the quality of life,protect the bone marrow,alleviate digestive tract reaction,and has no obvious adverse reactions.